Barclays Forecasts Strong Price Appreciation for Janux Therapeutics (NASDAQ:JANX) Stock

Janux Therapeutics (NASDAQ:JANX) had its price objective lifted by research analysts at Barclays from $14.00 to $15.00 in a report released on Friday, Benzinga reports. The brokerage presently has an “underweight” rating on the stock. Barclays‘s price objective suggests a potential downside of 14.92% from the company’s current price.

A number of other brokerages have also issued reports on JANX. Guggenheim dropped their target price on Janux Therapeutics from $58.00 to $55.00 and set a “buy” rating on the stock in a research report on Friday, August 7th. Wolfe Research raised Janux Therapeutics from a “peer perform” rating to an “outperform” rating and set a $23.00 price target for the company in a research report on Monday, August 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Janux Therapeutics in a research report on Friday, October 16th. Stifel Nicolaus set a $35.00 price target on shares of Janux Therapeutics in a research note on Friday, August 7th. Finally, HC Wainwright reiterated a “buy” rating on shares of Janux Therapeutics in a report on Monday, October 19th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $36.92.

Janux Therapeutics Price Performance

Shares of Janux Therapeutics stock opened at $17.63 on Friday. The firm has a market cap of $1.08 billion, a price-to-earnings ratio of -11.09 and a beta of 2.44. The stock’s 50-day moving average is $17.49 and its 200-day moving average is $15.42. Janux Therapeutics has a one year low of $12.12 and a one year high of $35.34.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings data on Thursday, November 5th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.47) by $0.13. The firm had revenue of $9.29 million for the quarter, compared to analyst estimates of $8.03 million. On average, equities analysts expect that Janux Therapeutics will post -1.70 EPS for the current year.

Hedge Funds Weigh In On Janux Therapeutics

Large investors have recently modified their holdings of the business. BlackRock Inc. acquired a new position in shares of Janux Therapeutics during the 2nd quarter worth about $94,228,000. State Street Corp grew its holdings in shares of Janux Therapeutics by 22.0% in the 2nd quarter. State Street Corp now owns 3,004,899 shares of the company’s stock valued at $46,155,000 after acquiring an additional 540,882 shares in the last quarter. Alyeska Investment Group L.P. increased its position in shares of Janux Therapeutics by 2.9% in the second quarter. Alyeska Investment Group L.P. now owns 1,647,140 shares of the company’s stock valued at $25,300,000 after acquiring an additional 46,051 shares during the last quarter. Algert Global LLC increased its position in shares of Janux Therapeutics by 150.5% in the second quarter. Algert Global LLC now owns 1,110,889 shares of the company’s stock valued at $17,063,000 after acquiring an additional 667,492 shares during the last quarter. Finally, Bank of America Corp DE acquired a new stake in shares of Janux Therapeutics in the second quarter valued at about $13,985,000. 75.39% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Janux Therapeutics

Here are the key news stories impacting Janux Therapeutics this week:

• Positive Sentiment: Wedbush raised its price target to $40 from $36 and reiterated its outperform rating, implying substantial upside from the cited $17.63 share price. Wedbush raises Janux price target
• Positive Sentiment: Truist raised its target to $27 from $26 and maintained a buy rating, signaling continued confidence in JANX. Truist analyst recommendations
• Positive Sentiment: Janux reported a third-quarter loss of $0.34 per share, narrower than analysts’ expected loss of $0.45–$0.47. Revenue of $9.29 million also exceeded the $8.03 million estimate. The results beat expectations, although the company remained loss-making. Janux third-quarter 2026 results
• Neutral Sentiment: Janux said it dosed the first patient in the Phase 1 study of JANX013 in combination with JANX007, marking progress in its clinical pipeline; the update does not establish how the treatment will perform. Janux business highlights
• Negative Sentiment: Barclays raised its target only to $15 from $14 but kept an underweight rating, placing its target below the cited share price and underscoring a bearish view that contrasts with other analysts. Barclays analyst recommendations

About Janux Therapeutics

Janux Therapeutics, Inc is a clinical-stage biopharmaceutical company developing immune-based medicines for the treatment of cancer and autoimmune diseases. The company’s research is focused on designing therapies that selectively activate the immune system in diseased tissue while limiting activity in healthy tissue.

Janux’s proprietary technology platform is designed to create tumor-activated T-cell engager therapies and other immunomodulators. These medicines are engineered to remain relatively inactive in the circulation and become activated in the tumor microenvironment, with the goal of improving the therapeutic window of immune therapies.